BEAM

In September 2026, the company presented updated clinical data from the Phase 1/2 trial of BEAM-302, revealing a safety signal (transient liver enzyme elevations) alongside encouraging efficacy, which led to a -9.54% change in stock price. Also in September 2026, Beam Therapeutics appointed Eric Foster as Chief Commercial Officer, followed by a -1.36% change in stock price. In August 2026, ARK Investment and Cathie Wood reported a 9.95% stake, and Farallon funds reported a 9.99% position. In August 2026, the company reported its second-quarter 2026 financial results, detailing a wider-than-expected loss and missed revenue estimates. In July 2026, Beam Therapeutics' CMO sold 16,667 shares under a 10b5-1 plan, and insiders sold approximately $10.5 million of stock over the last quarter. In May 2026, the company announced updated safety and efficacy data from the ongoing Phase 1/2 trial of BEAM-302, showing robust increases in total AAT and a well-tolerated safety profile. In March 2026, Beam Therapeutics provided a BEAM-302 topline data update.